GVS assessment of trientine dihydrochloride (Cufence®) for the treatment of Wilson’s disease

Zorginstituut Nederland has completed its assessment whether trientine dihydrochloride (Cufence®) can be included in the Medicine Reimbursement System (GVS). The Zorginstituut recommends to include trientine dihydrochloride (Cufence®) in the GVS on list 1A in a new cluster to be formed together with trientine tetrahydrochloride (Cuprior®).

Registered indication

Trientine dihydrochloride (Cufence®) is indicated for the treatment of Wilson’s disease. 

Zorgintituut's advice

Based on the considerations mentioned in the report, Zorginstituut Nederland advises to include trientine dihydrochloride (Cufence®) in the GVS on list 1A in a new cluster to be formed together with trientine tetrahydrochloride (Cuprior®). The standard dose of Cufence® can be determined at 800 mg and that of Cuprior® at 450 mg.

The reimbursement of trientine is subject to a further condition. 
The present terms of reimbursement are as follows.
124. Trientine

Condition

To be used exclusively for insured persons with Wilson’s disease for whom therapy with D-penicillamine at the maximum tolerated dose is not sufficient.

These further conditions also apply to Cufence®; the text on List 2 can therefore remain unchanged.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.